We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Inflamyloid in Alzheimer's disease: from the amyloid cascade to neuroinflammation


Inflamyloid in Alzheimer's disease: from the amyloid cascade to neuroinflammation

Who's speaking at this Webinar?

Damian Crowther
Director R&D, Neuroscience IMED Biotech Unit, AstraZeneca

Alzheimer’s is defined by the production of amyloid beta peptides that are prone to aggregation. However, clinical approaches that seek to directly intervene in amyloid production have been largely, but not completely, unsuccessful.

Some investigators now question whether amyloid is the primary toxin; perhaps, instead, it is the brain’s protective responses that result in neurodegeneration?

The innate immune system is one response that is both powerful, for good or evil, and has been implicated by the latest genetic evidence. I will review some of the basic biology and the therapeutic interventions that are shedding light on the role of amyloid and inflammation in Alzheimer’s disease.

Key Learning objectives:

  • Understand how amyloid plaques are generated and what the resulting therapeutic targets have been
  • Gain an overview of recent amyloid-based trials – for small and large molecules
  • Learn how genomics has implicated innate immunity in Alzheimer’s disease
  • Hear about the role of TREM2 in Alzheimer’s and other neurodegenerative disorders
  • Develop a view on whether blocking amyloid or inflammation is the better strategy

Webinar Sponsored by:


Like what you just read? You can find similar content on the communities below.


To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free